TOPLINE:

Canagliflozin , an SGLT2 inhibitor, significantly reduced A1c levels in children and adolescents with type 2 diabetes (T2D) compared with placebo after 26 weeks. More participants who received canagliflozin achieved the A1c goal of less than 6.5% or 7.0% than those who received placebo at week 26.

METHODOLOGY:

A phase 3 randomized controlled trial was conducted across 104 sites in 10 countries and enrolled 171 participants (aged ≥ 10 years to < 18 years) with T2D and A1c levels between ≥ 6.5% and ≤ 11%.

Eligible participants had inadequate glycemic control despite following a diet and exercise regimen alone or in combination with receiving stable doses of metformin , insulin , or both.

Participants were randomly assigned to receive either 100 mg oral canagliflozin

See Full Page